{
  "id": 20431672,
  "title": "Roche enters the SERD market with FDA approval in late-stage breast cancer",
  "url": "https://urgent.news/2026/11/17/roche-enters-the-serd-market-with-fda-approval-in-late-stage-breast",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-17T12:00:39.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/roche-enters-the-serd-market-with-fda-approval-in-late-stage-breast-cancer/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Roche’s big-hope breast cancer pill giredestrant was in an odd situation in that it was awaiting two different FDA approval decisions. Also oddly, the second one came first. The drug was",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}